Merck Announces Commitment to Canadian Life Sciences Research Innovation Sector

Merck Canada will make an announcement today at the BIO International Convention regarding its plans to invest in the Canadian life sciences research innovation sector by providing $4 million to the Institute for Research in Immunology and Cancer – Commercialization of Research.

As quoted in the press release:

IRICoR will work in conjunction with MaRS Innovation and the Centre for Drug Research and Development (CDRD) to identify, develop and commercialize technologies in healthcare. All three CECR institutions – identified as CECR in 2008 by the federal government – share a common objective: facilitating and accelerating the commercialization of research breakthroughs that will improve the quality of life of Canadians and others around the world.

Click here to read the full Merck Canada press release.